JP2024523290A5 - - Google Patents
Info
- Publication number
- JP2024523290A5 JP2024523290A5 JP2023577156A JP2023577156A JP2024523290A5 JP 2024523290 A5 JP2024523290 A5 JP 2024523290A5 JP 2023577156 A JP2023577156 A JP 2023577156A JP 2023577156 A JP2023577156 A JP 2023577156A JP 2024523290 A5 JP2024523290 A5 JP 2024523290A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- masked
- type
- mask
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163259105P | 2021-06-18 | 2021-06-18 | |
| US63/259,105 | 2021-06-18 | ||
| PCT/US2022/000011 WO2022265679A2 (en) | 2021-06-18 | 2022-06-17 | FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523290A JP2024523290A (ja) | 2024-06-28 |
| JP2024523290A5 true JP2024523290A5 (https=) | 2025-06-24 |
Family
ID=82786512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577156A Pending JP2024523290A (ja) | 2021-06-18 | 2022-06-17 | がんの処置およびその方法における使用のための、マスクされたＩ型インターフェロン（ＩＦＮαおよびＩＦＮβ）を含む融合タンパク質組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250325634A1 (https=) |
| EP (1) | EP4329794A2 (https=) |
| JP (1) | JP2024523290A (https=) |
| KR (1) | KR20240021943A (https=) |
| CN (1) | CN117529330A (https=) |
| AU (1) | AU2022292462A1 (https=) |
| CA (1) | CA3221878A1 (https=) |
| IL (1) | IL308959A (https=) |
| WO (1) | WO2022265679A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024301163A1 (en) * | 2023-07-25 | 2026-02-05 | TJ Biopharma (Shanghai) Co., Ltd. | Masked interferon fusion proteins and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| BRPI0509274A (pt) | 2004-03-26 | 2007-09-04 | Pfizer Prod Inc | usos de anticorpos anti-ctla-4 |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| EP3955957A1 (en) * | 2019-04-15 | 2022-02-23 | Qwixel Therapeutics LLC | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
-
2022
- 2022-06-17 CA CA3221878A patent/CA3221878A1/en active Pending
- 2022-06-17 WO PCT/US2022/000011 patent/WO2022265679A2/en not_active Ceased
- 2022-06-17 IL IL308959A patent/IL308959A/en unknown
- 2022-06-17 CN CN202280043419.8A patent/CN117529330A/zh active Pending
- 2022-06-17 JP JP2023577156A patent/JP2024523290A/ja active Pending
- 2022-06-17 KR KR1020247001492A patent/KR20240021943A/ko active Pending
- 2022-06-17 US US18/445,651 patent/US20250325634A1/en active Pending
- 2022-06-17 EP EP22750926.2A patent/EP4329794A2/en active Pending
- 2022-06-17 AU AU2022292462A patent/AU2022292462A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7820448B2 (ja) | 新規のサイトカインプロドラッグ | |
| JP2022529943A5 (https=) | ||
| JP7682150B2 (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| JP2022536898A (ja) | 新規ｉｌ－１５プロドラッグおよびその使用方法 | |
| JP2024167313A5 (https=) | ||
| WO2021035188A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
| JP2023504914A5 (https=) | ||
| JP2020519643A5 (https=) | ||
| CN110740754A (zh) | 一种抗间皮素抗体及其抗体药物缀合物 | |
| CN1089606C (zh) | 一种修饰的超抗原和一种寻找靶物化合物的缀合物和该缀合物的用途 | |
| JP2022512043A5 (https=) | ||
| JP2022513384A5 (https=) | ||
| JP2021508449A5 (https=) | ||
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| CN114127117B (zh) | 用于偶联的多肽复合物及其应用 | |
| EP4277707A1 (en) | Interferon prodrugs and methods of making and using the same | |
| JP2024501894A5 (https=) | ||
| US6703488B1 (en) | Antibody/receptor targeting moiety for enhanced delivery of armed ligand | |
| JP2008515889A5 (https=) | ||
| JP2024517871A (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| EP1045861B1 (en) | Bispecific targeting moiety comprising an antibody to carcinoembryonic antigen (cea) and the ligand-binding region of the il13 receptor alpha subunit | |
| JP2024509241A5 (https=) | ||
| JP2022538894A5 (https=) | ||
| JP2024501771A5 (https=) | ||
| JP2025124718A5 (https=) |